Antiphospholipid Syndrome

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1  A |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | S |  |  |
|  |  |  |  |  |  |  |  |  |  | 2  S |  |  |  |  |  |  | P |  |  |
|  |  |  |  |  |  |  |  | 3  P |  | L |  |  |  | 4  B |  |  | I |  |  |
|  |  |  |  |  |  | 5  T | H | R | E | E |  |  |  | E |  |  | R |  |  |
|  |  |  |  |  |  |  |  | E |  |  |  | 6  S |  | T |  |  | I |  |  |
|  |  |  |  |  |  |  |  | G |  |  | 7  H | E | P | A | R | I | N |  |  |
|  |  |  |  |  |  |  |  | N |  |  |  | C |  |  |  |  |  |  |  |
|  |  |  |  |  | 8  C | 9  A | T | A | S | 10  T | R | O | P | H | I | C |  |  |  |
|  |  |  |  |  |  | U |  | N |  | H |  | N |  |  |  |  |  |  |  |
|  |  | 11  G | E | N | E | T | I | C |  | R |  | D |  | 12  L | U | P | U | S |  |
|  |  |  |  |  |  | O |  | Y |  | O |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  | I |  |  |  | M |  | 13  E |  |  |  |  |  |  |  |
|  |  |  |  |  |  | M |  |  |  | B |  | L |  |  |  |  |  |  |  |
|  |  |  |  |  |  | M |  | 14  T | W | O | H | I | T |  |  |  |  |  |  |
|  |  |  |  |  |  | U |  |  |  | S |  | S |  |  |  |  |  |  |  |
|  |  |  |  |  |  | N |  |  |  | I |  | A |  |  |  |  |  |  |  |
|  |  |  |  |  |  | E |  |  |  | S |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

|  |  |
| --- | --- |
| **Across**  **5.** How many known APL antibodies are there?  **7.** Pregnancy management for thrombosis is low molecular weight or unfractionated \_\_\_\_\_  **8.** \_\_\_\_\_\_APLS is rare but life threatening complication of APLS  **11.** Risk factor of primary APLS is \_\_\_\_\_\_marker HLA-DR7  **12.** Liquid phase coagulation assay to detect APLS by\_\_\_\_\_\_anticoagulant  **14.** A theory explained about thrombus formation in patients with APLS is | **Down**  **1.** Treatment for inhibit platelet activation is  **2.** Risk factor of Secondary APLS (40%) is  **3.** Arterial and venous thrombus and /or \_\_\_\_\_\_\_\_loss are hallmark of APLS.  **4.** Most common antibody seen in APLS are anti \_\_\_\_\_2 glycoprotein antibody  **6.** Pregnancy loss in patients with APLS is common in \_\_\_\_\_\_\_\_or third trimester  **9.** APLS is a multi systemic \_\_\_\_ disorder  **10.** Antiphospholipid syndrome provokes \_\_\_\_\_\_in arteries and veins.  **13.** Solid phase assay to detect APLS is |